Ovarian
Featured Articles
(PharmaTimes [UK]) Mar 20, 2019 - Merck and Pfizer are pulling the plug on a late-stage trial assessing the potential of their PD-L1 antibody avelumab in ovarian cancer front-line maintenance setting. The Phase III JAVELIN Ovarian PARP 100 study was evaluating the efficacy and safety of avelumab in combination with chemotherapy...
Read Article
(Pfizer) Mar 19, 2019 - Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by...
Read Article
Latest Articles
March 20, 2019
March 20, 2019
March 20, 2019
March 20, 2019
March 19, 2019
March 19, 2019
March 18, 2019
March 18, 2019
View More
News Commentary
Editor Image
05 Dec, 2018 | by Debu Tripathy, MD
Very interesting
View Comment
Editor Image
05 Apr, 2018 | by Winston Wong, PharmD
From a payer perspective, the CMS approval for coverage means that...
View Comment
View More
Featured Videos
There are no Ovarian videos.
OBR Blog
There are no Ovarian blog entries.